# First in Human Multicenter Open Name Dose-increase, Consolidation Method to Study Safety Drug-level in Blood & Drug Metabolism Clinical Activity of Oral JBI-778 in Lung Cancer Patients With, Without Brain Metastasis IDH Mutated WHO Grade 3,4 Recurrent Glioma, Salivary Glands Tumor

> **NCT07755397** · PHASE1 · RECRUITING · sponsor: **Jubilant Therapeutics India Limited** · enrollment: 30 (estimated)

## Conditions studied

- NSCLC Patients With EGFR Activating Mutation
- Adenoid Cystic Carcinoma Metastatic
- Adenoid Cystic Carcinoma of the Head and Neck

## Interventions

- **DRUG:** JBI-778

## Key facts

- **NCT ID:** NCT07755397
- **Lead sponsor:** Jubilant Therapeutics India Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-08-26
- **Primary completion:** 2028-03
- **Final completion:** 2028-04
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-08-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07755397

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07755397, "First in Human Multicenter Open Name Dose-increase, Consolidation Method to Study Safety Drug-level in Blood & Drug Metabolism Clinical Activity of Oral JBI-778 in Lung Cancer Patients With, Without Brain Metastasis IDH Mutated WHO Grade 3,4 Recurrent Glioma, Salivary Glands Tumor". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07755397. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*